You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Author Index Volume 2 (2015)

Abicht, A., see Ørstavik, K. (2) 181–184

Accorsi, A., T. Mehuron, A. Kumar, Y. Rhee and M. Girgenrath, Integrin dysregulation as a possible driver of matrix remodeling in Laminin-deficient congenital muscular dystrophy (MDC1A) (1) 51–61

Alexander, M.S. and L.M. Kunkel, “Skeletal Muscle MicroRNAs: Their Diagnostic and Therapeutic Potential in Human Muscle Diseases” (1) 1–11

Allamand, V., see Nelson, I. (3) 229–240

Allen, P., see Cacheux, M. (4) 421–432

Allenbach, Y. and O. Benveniste, Diagnostic Utility of Auto-Antibodies in Inflammatory Muscle Diseases (1) 13–25

Alston, C.L., see Wesolowska, M. (4) 409–419

Al-Zaidy, S.A., Z. Sahenk, L.R. Rodino-Klapac, B. Kaspar and J.R. Mendell, Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy (3) 185–192

Ander, B.P., see Liu, D.Z. (4) 387–396

Annoussamy, M., see Servais, L. (3) 269–279

Apponi, L.H., see Vest, K.E. (4) 439–446

Azzi, V., see Catteruccia, M. (4) 453–462

Babuty, D., see Nelson, I. (3) 229–240

Banerjee, A., see Vest, K.E. (4) 439–446

Barnett, C., I.S.J. Merkies, H. Katzberg and V. Bril, Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale (3) 301–311

Barnett, C., see Kassardjian, C.D. (1) 93–97

Barthélémy, F., C. Blouin, N. Wein, V. Mouly, S. Courrier, E. Dionnet, V. Kergourlay, Y. Mathieu, L. Garcia, G. Butler-Browne, C. Lamaze, N. Lévy, M. Krahn and M. Bartoli, Exon 32 Skipping of Dysferlin Rescues Membrane Repair in Patients’ Cells (3) 281–290

Bartoli, M., see Barthélémy, F. (3) 281–290

Bartoli, M., see Cerino, M. (2) 131–136

Bates, M.G., see Newman, J. (2) 151–155

Battle, D., see Renusch, S.R. (2) 119–130

Bécane, H.-M., see Nelson, I. (3) 229–240

Beggs, A.H., see Ceyhan-Birsoy, O. (1) 87–92

Béhin, A., see Cerino, M. (2) 131–136

Bell, C.F., see Landfeldt, E. (1) 63–72

Bennett, D., see Burch, P.M. (3) 241–255

Benveniste, O., see Allenbach, Y. (1) 13–25

Bernard, R., see Cerino, M. (2) 131–136

Béroud, C., see Nelson, I. (3) 229–240

Bertini, E., see Catteruccia, M. (4) 453–462

Beuvin, M., see Malfatti, E. (3) 219–227

Biancalana, V. and J. Laporte, Diagnostic use of Massively Parallel Sequencing in Neuromuscular Diseases: Towards an Integrated Diagnosis (3) 193–203

Blouin, C., see Barthélémy, F. (3) 281–290

Blum, A., see Cacheux, M. (4) 421–432

Böhm, J., see Malfatti, E. (3) 219–227

Bonne, G., see Nelson, I. (3) 229–240

Bouchet-Séraphin, C., S. Vuillaumier-Barrot and N. Seta, Dystroglycanopathies: About Numerous Genes Involved in Glycosylation of One Single Glycoprotein (1) 27–38

Breton, R., see Denicourt, M. (1) 99–105

Bril, V., see Barnett, C. (3) 301–311

Bril, V., see Kassardjian, C.D. (1) 93–97

Brocard, J., see Cacheux, M. (4) 421–432

Brochier, G., see Malfatti, E. (3) 219–227

Brochier, G., see Richard, P. (2) 175–180

Browne, G.B., see Thorley, M. (3) 205–217

Burch, P.M., O. Pogoryelova, R. Goldstein, D. Bennett, M. Guglieri, V. Straub, K. Bushby, H. Lochmüller and C. Morris, Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy (3) 241–255

Bushby, K., see Burch, P.M. (3) 241–255

Bushby, K., see Landfeldt, E. (1) 63–72

Butler-Browne, G., see Barthélémy, F. (3) 281–290

Butoianu, N., see Servais, L. (3) 269–279

Cacheux, M., A. Blum, M. Sébastien, A.S. Wozny, J. Brocard, K. Mamchaoui, V. Mouly, N. Roux-Buisson, J. Rendu, N. Monnier, R. Krivosic, P. Allen, A. Lacour, J. Lunardi, J. Fauré and I. Marty, Functional Characterization of a Central Core Disease RyR1 Mutation (p.Y4864H) Associated with Quantitative Defect in RyR1 Protein (4) 421–432

Campbell, C., see Wei, Y. (3) 313–324

Cances, C., see Servais, L. (3) 269–279

Carr, B., see Montes, J. (4) 463–470

Catteruccia, M., C. Vuillerot, I. Vaugier, D. Leclair, V. Azzi, L. Viollet, B. Estournet, E. Bertini and S. Quijano-Roy, Orthopedic Management of Scoliosis by Garches Brace and Spinal Fusion in SMA Type 2 Children (4) 453–462

Cerino, M., S. Gorokhova, A. Béhin, J.A. Urtizberea, V. Kergourlay, E. Salvo, R. Bernard, N. Lévy, M. Bartoli and M. Krahn, Novel Pathogenic Variants in a French Cohort Widen the Mutational Spectrum of GNE Myopathy (2) 131–136

Ceyhan-Birsoy, O., B. Talim, L.C. Swanson, M. Karakaya, M.A. Graff, A.H. Beggs and H. Topaloglu, Whole Exome Sequencing Reveals DYSF, FKTN, and ISPD Mutations in Congenital Muscular Dystrophy Without Brain or Eye Involvement (1) 87–92

Chadwick, J.A., see Lowe, J. (3) 257–268

Chen, W., see Johnson, N.E. (4) 447–452

Chinnery, P.F., see Wesolowska, M. (4) 409–419

Chrzanowska-Lightowlers, Z.M., see Wesolowska, M. (4) 409–419

Ciafaloni, E., see Johnson, N.E. (4) 447–452

Corbett, A.H., see Vest, K.E. (4) 439–446

Courrier, S., see Barthélémy, F. (3) 281–290

Cruz, R., see Montes, J. (4) 463–470

Cuisset, J.-M., see Servais, L. (3) 269–279

de Groot, I.J.M., see van den Engel-Hoek, L. (4) 357–369

De Luca, A., see Willmann, R. (2) 113–117

de Swart, B.J.M., see van den Engel-Hoek, L. (4) 357–369

De Vivo, D.C., see Montes, J. (4) 463–470

Deenen, J.C.W., C.G.C. Horlings, J.J.G.M. Verschuuren, A.L.M. Verbeek and B.G.M. van Engelen, The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature (1) 73–85

Delmont, E. and H. Willison, Diagnostic Utility of Auto Antibodies in Inflammatory Nerve Disorders (2) 107–112

Delmont, E., see Galban-Horcajo, F. (2) 157–165

Demay, L., see Richard, P. (2) 175–180

Denicourt, M., M.T. Pham, J. Mathieu and R. Breton, DM1 Patients with Small CTG Expansions are also at Risk of Severe Conduction Abnormalities (1) 99–105

Dionnet, E., see Barthélémy, F. (3) 281–290

Duan, D., see Hakim, C.H. (4) 397–407

Duddy, W., see Thorley, M. (3) 205–217

Duguez, S., see Thorley, M. (3) 205–217

Dunaway, S., see Montes, J. (4) 463–470

Elsheikh, B.H., see Renusch, S.R. (2) 119–130

Erasmus, C.E., see van den Engel-Hoek, L. (4) 357–369

Estournet, B., see Catteruccia, M. (4) 453–462

Eymard, B., see Nelson, I. (3) 229–240

Eymard, B., see Richard, P. (2) 175–180

Fardeau, M., see Richard, P. (2) 175–180

Fauré, J., see Cacheux, M. (4) 421–432

Feng, F., see Hakim, C.H. (4) 397–407

Ferrer-Monasterio, X., see Richard, P. (2) 175–180

Floyd, K.T., see Lowe, J. (3) 257–268

Freitas, M.A., see Renusch, S.R. (2) 119–130

Fricke, A.F., see Statland, J.M. (3) 291–299

Galban-Horcajo, F., L. Vlam, E. Delmont, S.K. Halstead, L. van den Berg, W-L. van der Pol and H.J. Willison, The Diagnostic Utility of Determining Anti-GM1: GalC Complex Antibodies in Multifocal Motor Neuropathy: A Validation Study (2) 157–165

Galna, B., see Newman, J. (2) 151–155

Garber, C.E., see Montes, J. (4) 463–470

Garcia, L., see Barthélémy, F. (3) 281–290

Gardner, B.B., K.A. Swaggart, G. Kim, S. Watson and E.M. McNally, Cardiac function in muscular dystrophy associates with abdominal muscle pathology (1) 39–49

Gidaro, T., see Richard, P. (2) 175–180

Gidaro, T., see Servais, L. (3) 269–279

Girgenrath, M., see Accorsi, A. (1) 51–61

Goldstein, R., see Burch, P.M. (3) 241–255

Gorman, G.S., see Newman, J. (2) 151–155

Gorman, G.S., see Wesolowska, M. (4) 409–419

Gorokhova, S., see Cerino, M. (2) 131–136

Graff, M.A., see Ceyhan-Birsoy, O. (1) 87–92

Griffin, H., see Wesolowska, M. (4) 409–419

Guglieri, M., see Burch, P.M. (3) 241–255

Guglieri, M., see Landfeldt, E. (1) 63–72

Hagerman, K.A., see Johnson, N.E. (4) 447–452

Hakim, C.H., A.A. Peters, F. Feng, G. Yao and D. Duan, Night Activity Reduction is a Signature Physiological Biomarker for Duchenne Muscular Dystrophy Dogs (4) 397–407

Halicek, M.T., see Pfohl, S.R. (2) 137–150

Halstead, S.K., see Galban-Horcajo, F. (2) 157–165

Harshman, S., see Renusch, S.R. (2) 119–130

He, L., see Wesolowska, M. (4) 409–419

Heatwole, C.R., see Johnson, N.E. (4) 447–452

Henderson, D., see Statland, J.M. (3) 291–299

Hogrel, J.-Y., see Servais, L. (3) 269–279

Horlings, C.G.C., see Deenen, J.C.W. (1) 73–85

Hotta, A., Genome Editing Gene Therapy for Duchenne Muscular Dystrophy (4) 343–355

Hu, S., see Liu, D.Z. (4) 387–396

Hung, M., see Johnson, N.E. (4) 447–452

Hyzewicz, J., U.T. Ruegg and S. Takeda, Comparison of Experimental Protocols of Physical Exercise for mdx Mice and Duchenne Muscular Dystrophy Patients (4) 325–342

Jakovljevic, D.G., see Newman, J. (2) 151–155

Janssen, P.M.L., see Lowe, J. (3) 257–268

Jewell, D., see Kassardjian, C.D. (1) 93–97

Jickling, G.C., see Liu, D.Z. (4) 387–396

Johnson, N.E., M. Hung, E. Nasser, K.A. Hagerman, W. Chen, E. Ciafaloni and C.R. Heatwole, The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study (4) 447–452

Kamil-Rosenberg, S., see Montes, J. (4) 463–470

Karakaya, M., see Ceyhan-Birsoy, O. (1) 87–92

Kaspar, B., see Al-Zaidy, S.A. (3) 185–192

Kassardjian, C.D., S. Kokokyi, C. Barnett, D. Jewell, V. Bril, B.J. Murray and H.D. Katzberg, Excessive Daytime Sleepiness in Patients with Myasthenia Gravis (1) 93–97

Katzberg, H., see Barnett, C. (3) 301–311

Katzberg, H.D., see Kassardjian, C.D. (1) 93–97

Kergourlay, V., see Barthélémy, F. (3) 281–290

Kergourlay, V., see Cerino, M. (2) 131–136

Kerty, E., see Ørstavik, K. (2) 181–184

Kiiski, K., V-L. Lehtokari, A.Y. Manzur, C. Sewry, I. Zaharieva, F. Muntoni, K. Pelin and C. Wallgren-Pettersson, A Large Deletion Affecting TPM3, Causing Severe Nemaline Myopathy (4) 433–438

Kim, G., see Gardner, B.B. (1) 39–49

Kissel, J.T., see Renusch, S.R. (2) 119–130

Klein, A., see Servais, L. (3) 269–279

Kokokyi, S., see Kassardjian, C.D. (1) 93–97

Kolb, S.J., see Renusch, S.R. (2) 119–130

Krahn, M., see Barthélémy, F. (3) 281–290

Krahn, M., see Cerino, M. (2) 131–136

Kramer, S.S., see Montes, J. (4) 463–470

Krivosic, R., see Cacheux, M. (4) 421–432

Kumar, A., see Accorsi, A. (1) 51–61

Kunkel, L.M., see Alexander, M.S. (1) 1–11

Lacène, E., see Malfatti, E. (3) 219–227

Lacour, A., see Cacheux, M. (4) 421–432

Laforêt, P., see Richard, P. (2) 175–180

Lamaze, C., see Barthélémy, F. (3) 281–290

Landfeldt, E., P. Lindgren, C.F. Bell, C. Schmitt, M. Guglieri, V. Straub, H. Lochmüller and K. Bushby, Compliance to Care Guidelines for Duchenne Muscular Dystrophy (1) 63–72

Laporte, J., see Biancalana, V. (3) 193–203

Laporte, J., see Malfatti, E. (3) 219–227

Laugel, V., see Servais, L. (3) 269–279

Le Gall, L., see Thorley, M. (3) 205–217

Le Guiner, C., see Servais, L. (3) 269–279

Le Moing, A.-G., see Servais, L. (3) 269–279

Leclair, D., see Catteruccia, M. (4) 453–462

Lehtokari, V-L., see Kiiski, K. (4) 433–438

Leturcq, F., see Nelson, I. (3) 229–240

Leturcq, F., see Servais, L. (3) 269–279

Lévy, N., see Barthélémy, F. (3) 281–290

Lévy, N., see Cerino, M. (2) 131–136

Li, X., see Renusch, S.R. (2) 119–130

Lightowlers, R.N., see Wesolowska, M. (4) 409–419

Lindgren, P., see Landfeldt, E. (1) 63–72

Liu, D.Z., B. Stamova, S. Hu, B.P. Ander, G.C. Jickling, X. Zhan, F.R. Sharp and B. Wong, MicroRNA and mRNA Expression Changes in Steroid Naïve and Steroid Treated DMD Patients (4) 387–396

Lochmüller, H., see Burch, P.M. (3) 241–255

Lochmüller, H., see Landfeldt, E. (1) 63–72

Lowe, J., A.J. Wodarcyk, K.T. Floyd, N. Rastogi, E.J. Schultz, S.A. Swager, J.A. Chadwick, T. Tran, S.V. Raman, P.M.L. Janssen and J.A. Rafael-Fortney, The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy (3) 257–268

Lunardi, J., see Cacheux, M. (4) 421–432

Malatras, A., see Thorley, M. (3) 205–217

Malfatti, E., J. Böhm, E. Lacène, M. Beuvin, G. Brochier, N.B. Romero and J. Laporte, A Premature Stop Codon in MYO18B is Associated with Severe Nemaline Myopathy with Cardiomyopathy (3) 219–227

Malfatti, E., see Richard, P. (2) 175–180

Mamchaoui, K., see Cacheux, M. (4) 421–432

Manzur, A.Y., see Kiiski, K. (4) 433–438

Martin-Négrier, M.-L., see Richard, P. (2) 175–180

Marty, I., see Cacheux, M. (4) 421–432

Mathieu, J., see Denicourt, M. (1) 99–105

Mathieu, Y., see Barthélémy, F. (3) 281–290

McFarland, R., see Newman, J. (2) 151–155

McNally, E.M., see Gardner, B.B. (1) 39–49

Mehuron, T., see Accorsi, A. (1) 51–61

Mendell, J.R., see Al-Zaidy, S.A. (3) 185–192

Merkies, I.S.J., see Barnett, C. (3) 301–311

Miller, J.A.L., see Wesolowska, M. (4) 409–419

Mitchell, C.S., see Pfohl, S.R. (2) 137–150

Monnier, N., see Cacheux, M. (4) 421–432

Montes, J., C.E. Garber, S.S. Kramer, M.J. Montgomery, S. Dunaway, S. Kamil-Rosenberg, B. Carr, R. Cruz, N.E. Strauss, D. Sproule and D.C. De Vivo, Single-Blind, Randomized, Controlled Clinical Trial of Exercise in Ambulatory Spinal Muscular Atrophy: Why are the Results Negative? (4) 463–470

Montgomery, M.J., see Montes, J. (4) 463–470

Montus, M., see Servais, L. (3) 269–279

Moraux, A., see Servais, L. (3) 269–279

Morris, C., see Burch, P.M. (3) 241–255

Moullier, P., see Servais, L. (3) 269–279

Mouly, V., see Barthélémy, F. (3) 281–290

Mouly, V., see Cacheux, M. (4) 421–432

Mouly, V., see Thorley, M. (3) 205–217

Moyer, A.L. and K.R. Wagner, Mammalian Mss51 is a Skeletal Muscle-Specific Gene Modulating Cellular Metabolism (4) 371–385

MS Tomé, F., see Richard, P. (2) 175–180

Muntoni, F., see Kiiski, K. (4) 433–438

Murray, B.J., see Kassardjian, C.D. (1) 93–97

Nagaraju, K., see Willmann, R. (2) 113–117

Nasser, E., see Johnson, N.E. (4) 447–452

Nelson, I., T. Stojkovic, V. Allamand, F. Leturcq, H.-M. Bécane, D. Babuty, A. Toutain, C. Béroud, P. Richard, N.B. Romero, B. Eymard, R.B. Yaou and G. Bonne, Laminin α2 Deficiency-Related Muscular Dystrophy Mimicking Emery-Dreifuss and Collagen VI related Diseases (3) 229–240

Newman, J., B. Galna, D.G. Jakovljevic, M.G. Bates, A.M. Schaefer, R. McFarland, D.M. Turnbull, M.I. Trenell, R.W. Taylor, L. Rochester and G.S. Gorman, Preliminary Evaluation of Clinician Rated Outcome Measures in Mitochondrial Disease (2) 151–155

Odrzywolski, K.J., see Statland, J.M. (3) 291–299

Ørstavik, K., S.C. Wallace, T. Torbergsen, A. Abicht, S.E. Tangsrud, E. Kerty and M. Rasmussen, A de novo Mutation in the SCN4A Gene Causing Sodium Channel Myotonia (2) 181–184Pajak, A., see Wesolowska, M. (4) 409–419

Parthun, M.R., see Renusch, S.R. (2) 119–130

Pavlath, G.K., see Vest, K.E. (4) 439–446

Pelin, K., see Kiiski, K. (4) 433–438

Peters, A.A., see Hakim, C.H. (4) 397–407

Petri, H., see Werlauff, U. (2) 167–174

Pfohl, S.R., M.T. Halicek and C.S. Mitchell, Characterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis (2) 137–150

Pham, M.T., see Denicourt, M. (1) 99–105

Pi, H., see Renusch, S.R. (2) 119–130

Pogoryelova, O., see Burch, P.M. (3) 241–255

Prior, T.W., see Renusch, S.R. (2) 119–130

Pyle, A., see Wesolowska, M. (4) 409–419Quijano-Roy, S., see Catteruccia, M. (4) 453–462

Rafael-Fortney, J.A., see Lowe, J. (3) 257–268

Raman, S.V., see Lowe, J. (3) 257–268

Rasmussen, M., see Ørstavik, K. (2) 181–184

Rastogi, N., see Lowe, J. (3) 257–268

Rendu, J., see Cacheux, M. (4) 421–432

Renusch, S.R., S. Harshman, H. Pi, E. Workman, A. Wehr, X. Li, T.W. Prior, B.H. Elsheikh, K.J. Swoboda, L.R. Simard, J.T. Kissel, D. Battle, M.R. Parthun, M.A. Freitas and S.J. Kolb, Spinal Muscular Atrophy Biomarker Measurements from Blood Samples in a Clinical Trial of Valproic Acid in Ambulatory Adults (2) 119–130

Rhee, Y., see Accorsi, A. (1) 51–61

Richard, P., C. Trollet, T. Gidaro, L. Demay, G. Brochier, E. Malfatti, F. MS Tomé, M. Fardeau, P. Laforêt, N. Romero, M.-L. Martin-Négrier, G. Solé, X. Ferrer-Monasterio, J.L. Saint-Guily and B. Eymard, PABPN1 (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy – Consequences in Clinical Diagnosis and Genetic Counselling (2) 175–180

Richard, P., see Nelson, I. (3) 229–240

Rochester, L., see Newman, J. (2) 151–155

Rodino-Klapac, L.R., see Al-Zaidy, S.A. (3) 185–192

Romero, N., see Richard, P. (2) 175–180

Romero, N.B., see Malfatti, E. (3) 219–227

Romero, N.B., see Nelson, I. (3) 229–240

Roux-Buisson, N., see Cacheux, M. (4) 421–432

Rüegg, M.A., see Willmann, R. (2) 113–117

Ruegg, U.T., see Hyzewicz, J. (4) 325–342

Sabouraud, P., see Servais, L. (3) 269–279

Sahenk, Z., see Al-Zaidy, S.A. (3) 185–192

Saint-Guily, J.L., see Richard, P. (2) 175–180

Salvo, E., see Cerino, M. (2) 131–136

Schaefer, A.M., see Newman, J. (2) 151–155

Schaefer, A.M., see Wesolowska, M. (4) 409–419

Schmitt, C., see Landfeldt, E. (1) 63–72

Schultz, E.J., see Lowe, J. (3) 257–268

Sébastien, M., see Cacheux, M. (4) 421–432

Seferian, A.M., see Servais, L. (3) 269–279

Servais, L., M. Montus, C. Le Guiner, R.B. Yaou, M. Annoussamy, A. Moraux, J.-Y. Hogrel, A.M. Seferian, K. Zehrouni, A.-G. Le Moing, T. Gidaro, C. Vanhulle, V. Laugel, N. Butoianu, J.-M. Cuisset, P. Sabouraud, C. Cances, A. Klein, F. Leturcq, P. Moullier and T. Voit, Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype (3) 269–279

Seta, N., see Bouchet-Séraphin, C. (1) 27–38

Sewry, C., see Kiiski, K. (4) 433–438

Shah, B., see Statland, J.M. (3) 291–299

Sharp, F.R., see Liu, D.Z. (4) 387–396

Simard, L.R., see Renusch, S.R. (2) 119–130

Solé, G., see Richard, P. (2) 175–180

Speechley, K., see Wei, Y. (3) 313–324

Sproule, D., see Montes, J. (4) 463–470

Stamova, B., see Liu, D.Z. (4) 387–396

Statland, J.M., K.J. Odrzywolski, B. Shah, D. Henderson, A.F. Fricke, S. van der Maarel, S.J. Tapscott and R. Tawil, Immunohistochemical Characterization of Facioscapulohumeral Muscular Dystrophy Muscle Biopsies (3) 291–299

Stojkovic, T., see Nelson, I. (3) 229–240

Straub, V., see Burch, P.M. (3) 241–255

Straub, V., see Landfeldt, E. (1) 63–72

Strauss, N.E., see Montes, J. (4) 463–470

Swager, S.A., see Lowe, J. (3) 257–268

Swaggart, K.A., see Gardner, B.B. (1) 39–49

Swanson, L.C., see Ceyhan-Birsoy, O. (1) 87–92

Swoboda, K.J., see Renusch, S.R. (2) 119–130

Takeda, S., see Hyzewicz, J. (4) 325–342

Talim, B., see Ceyhan-Birsoy, O. (1) 87–92

Tangsrud, S.E., see Ørstavik, K. (2) 181–184

Tapscott, S.J., see Statland, J.M. (3) 291–299

Tawil, R., see Statland, J.M. (3) 291–299

Taylor, R.W., see Newman, J. (2) 151–155

Taylor, R.W., see Wesolowska, M. (4) 409–419

Thorley, M., A. Malatras, W. Duddy, L. Le Gall, V. Mouly, G.B. Browne and S. Duguez, Changes in Communication between Muscle Stem Cells and their Environment with Aging (3) 205–217

Topaloglu, H., see Ceyhan-Birsoy, O. (1) 87–92

Torbergsen, T., see Ørstavik, K. (2) 181–184

Toutain, A., see Nelson, I. (3) 229–240

Tran, T., see Lowe, J. (3) 257–268

Trenell, M.I., see Newman, J. (2) 151–155

Trollet, C., see Richard, P. (2) 175–180

Turnbull, D.M., see Newman, J. (2) 151–155

Urtizberea, J.A., see Cerino, M. (2) 131–136

van den Berg, L., see Galban-Horcajo, F. (2) 157–165

van den Engel-Hoek, L., I.J.M. de Groot, B.J.M. de Swart and C.E. Erasmus, Feeding and Swallowing Disorders in Pediatric Neuromuscular Diseases: An Overview (4) 357–369

van der Maarel, S., see Statland, J.M. (3) 291–299

van der Pol, W-L., see Galban-Horcajo, F. (2) 157–165

van Engelen, B.G.M., see Deenen, J.C.W. (1) 73–85

Vanhulle, C., see Servais, L. (3) 269–279

Vaugier, I., see Catteruccia, M. (4) 453–462

Verbeek, A.L.M., see Deenen, J.C.W. (1) 73–85

Verschuuren, J.J.G.M., see Deenen, J.C.W. (1) 73–85

Vest, K.E., L.H. Apponi, A. Banerjee, G.K. Pavlath and A.H. Corbett, An Antibody to Detect Alanine-Expanded PABPN1: A New Tool to Study Oculopharyngeal Muscular Dystrophy (4) 439–446

Viollet, L., see Catteruccia, M. (4) 453–462

Vissing, J., see Werlauff, U. (2) 167–174

Vlam, L., see Galban-Horcajo, F. (2) 157–165

Voit, T., see Servais, L. (3) 269–279

Vuillaumier-Barrot, S., see Bouchet-Séraphin, C. (1) 27–38

Vuillerot, C., see Catteruccia, M. (4) 453–462

Wagner, K.R., see Moyer, A.L. (4) 371–385

Wallace, S.C., see Ørstavik, K. (2) 181–184

Wallgren-Pettersson, C., see Kiiski, K. (4) 433–438

Watson, S., see Gardner, B.B. (1) 39–49

Wehr, A., see Renusch, S.R. (2) 119–130

Wei, Y., K. Speechley and C. Campbell, Health-Related Quality of Life in Children with Duchenne Muscular Dystrophy: A Review (3) 313–324

Wein, N., see Barthélémy, F. (3) 281–290

Werlauff, U., H. Petri, N. Witting and J. Vissing, Frequency and Phenotype of Myotubular Myopathy Amongst Danish Patients with Congenital Myopathy Older than 5 Years (2) 167–174

Wesolowska, M., G.S. Gorman, C.L. Alston, A. Pajak, A. Pyle, L. He, H. Griffin, P.F. Chinnery, J.A.L. Miller, A.M. Schaefer, R.W. Taylor, R.N. Lightowlers and Z.M. Chrzanowska-Lightowlers, Adult Onset Leigh Syndrome in the Intensive Care Setting: A Novel Presentation of a C12orf65 Related Mitochondrial Disease (4) 409–419

Willison, H., see Delmont, E. (2) 107–112

Willison, H.J., see Galban-Horcajo, F. (2) 157–165

Willmann, R., A. De Luca, K. Nagaraju and M.A. Rüegg, Best Practices and Standard Protocols as a Tool to Enhance Translation for Neuromuscular Disorders (2) 113–117

Witting, N., see Werlauff, U. (2) 167–174

Wodarcyk, A.J., see Lowe, J. (3) 257–268

Wong, B., see Liu, D.Z. (4) 387–396

Workman, E., see Renusch, S.R. (2) 119–130

Wozny, A.S., see Cacheux, M. (4) 421–432

Yao, G., see Hakim, C.H. (4) 397–407

Yaou, R.B., see Nelson, I. (3) 229–240

Yaou, R.B., see Servais, L. (3) 269–279

Zaharieva, I., see Kiiski, K. (4) 433–438

Zehrouni, K., see Servais, L. (3) 269–279

Zhan, X., see Liu, D.Z. (4) 387–396